Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc (NYSE: BAX) is a global healthcare leader specializing in life-saving renal care, advanced medical devices, and hospital solutions. This page provides investors and healthcare professionals with timely updates on the company’s operational developments, regulatory milestones, and strategic initiatives.
Access authoritative information about Baxter’s latest financial results, product innovations, and partnerships. Our curated news collection simplifies tracking of critical updates across key areas including dialysis technologies, infusion systems, and biosurgery products.
Discover official announcements regarding:
• Quarterly earnings and financial guidance
• New product approvals and clinical trials
• Strategic acquisitions in medical technology
• Regulatory compliance updates
• Leadership changes and corporate governance
Bookmark this page for streamlined access to Baxter’s verified news developments. Check regularly for updates that may impact market positioning and healthcare sector trends.
Baxter International (NYSE:BAX) has appointed Dr. David S. Wilkes to its board of directors, enhancing its leadership with his extensive medical and biotech experience. Dr. Wilkes, dean of the University of Virginia School of Medicine, will serve on Baxter’s Quality, Compliance and Technology Committee. Albert P.L. Stroucken is named lead independent director, succeeding Thomas T. Stallkamp, who remains on the board. The changes reflect Baxter's commitment to diversify its board while maintaining experienced oversight. The board now consists of 13 members.
Baxter International (NYSE:BAX) has declared a quarterly cash dividend of $0.245 per share, payable on April 1, 2021, to shareholders on record as of February 26, 2021. This sets an annual indicative dividend rate at $0.98 per share. Baxter, with over 85 years of experience, focuses on critical care, nutrition, and surgical products, impacting millions globally. The company’s forward-looking statements suggest that future dividend payouts may vary based on several risk factors.
Baxter International reported fourth-quarter sales of $3.2 billion, a 5% year-over-year increase, despite a flat U.S. market. International sales rose 8%, driven by Acute Therapies demand during COVID-19. Fourth-quarter net income was $168 million or $0.33 per share, influenced by special items totaling $244 million. For 2020, sales reached $11.7 billion, up 3%, with net income of $1.1 billion. The company expects 2021 sales growth of 7-8% and adjusted earnings per share of $3.35 to $3.43. Baxter remains committed to shareholder value and innovation amidst ongoing challenges.
Baxter International (NYSE:BAX) will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 10:40 a.m. Eastern Time. Jay Saccaro, the company’s CFO, is scheduled to speak. A live webcast of the presentation will be available on www.baxter.com and can be replayed until May 25, 2021. Baxter has a legacy of over 85 years in transforming healthcare through innovations in critical care, nutrition, renal, and surgical products, serving patients in over 100 countries.
Baxter International has announced an agreement with Novavax to provide sterile manufacturing services for the COVID-19 vaccine candidate NVX-CoV2373. This partnership aims to support commercial-scale manufacturing for distribution in the UK and Europe. The facility in Halle/Westfalen, Germany, will ensure compliance with cGMP standards. Currently in phase 3 trials, the vaccine has not yet received authorization. Novavax's vaccine utilizes recombinant nanoparticle technology, aiming to provide a safe and effective solution amid the ongoing pandemic.
Baxter International Inc. (NYSE:BAX) announced a conference call to discuss its fourth-quarter 2020 financial results scheduled for February 4, 2021, at 7:30 a.m. Central Time. Interested participants can pre-register using the provided link or access the webcast via Baxter’s website. The call will be recorded and is copyrighted material.
Baxter has been a trusted provider of healthcare products for over 85 years, offering critical care, nutrition, and renal products in over 100 countries.
Baxter International (NYSE:BAX) will present at the 39th Annual J.P. Morgan Healthcare Conference via webcast. CEO José Almeida is scheduled to speak on January 11, 2021, at 9:10 a.m. ET. Investors can access the live webcast and slides at www.baxter.com, with replays available until February 11, 2021. Baxter has been a vital player in healthcare for over 85 years, providing critical care, nutrition, and surgical products across more than 100 countries.
Baxter International (NYSE:BAX) partners with AdventHealth Tampa to implement the Vital Edge program, expected to save the hospital approximately $200,000 annually. This program focuses on intraoperative hemostasis management, aiming to enhance clinical efficacy, operational efficiency, and financial performance. The initiative responds to growing concerns over surgical bleeding, which complicates patient outcomes and increases costs. Baxter's collaboration with AdventHealth aims to optimize the use of hemostatic agents, providing educational resources and data-driven insights for better hospital practices.
Baxter International Inc. (NYSE:BAX) announced a $50 million expansion of its sterile fill/finish manufacturing facilities in Bloomington, Indiana. This development, funded through Baxter and client investments, includes a new 25,000 sq. ft. warehouse, filling lines, and automated inspection lines. Construction is ongoing, with completion expected in 2021 and manufacturing set for 2022. The expansion will create approximately 100 new jobs at the site, enhancing Baxter's capabilities in sterile contract manufacturing for over 25 pharmaceutical companies.
Baxter International Inc. (NYSE:BAX) has received FDA clearance for its Homechoice Claria automated peritoneal dialysis (APD) system, featuring the Sharesource connectivity platform. This innovative system is designed for both adult and pediatric patients, enhancing remote patient management and promoting home dialysis growth. With over 6 million home dialysis treatments facilitated by Sharesource in the U.S., the new system aims to improve patient education and care efficiency. Homechoice Claria is slated for U.S. availability in the coming weeks.
